Current status of producing autologous hematopoietic stem cells

Hematopoietic stem cells (HSCs) transplantation is an established therapy for many diseases of the hemato- poietic system, for example aplastic anemia, acute myeloid leukemia and acute lymphoblastic leukemia. With the development of the HSCs research, HSCs provide an attractive method for treating hereditary blood disorders and immunotherapy of cancer by introducing gene modification. Compared with allogenic HSCs transplantation, using autologous HSCs or HSCs from induced pluripotent stem cells (iPSCs) would eliminate the probability of alloimmunization and transfusion-transmitted infectious diseases. The methods for obtain- ing autologous HSCs include amplifying patients' HSCs or inducing patients' somatic cells to HSCs (graph abstract). However, the biggest problem is inducing HSCs to proliferate in vitro and maintaining their stem- ness at the same time. Although many tests have been made to transform iPSCs to HSCs, the artificially gener- ated HSCs still have substantial disparity compared with physiological HSCs. This review summarized the application status and obstacles to implantation of autologous HSCs and iPSC-derived HSCs. Meanwhile, we summarized the latest research progress in HSCs amplification and iPSCs reprogramming methods, which will help to solve the problems mentioned above.(c) 2023 Published by Elsevier Masson SAS.

Automated summary

Hematopoietic stem cell transplantation is an established therapy for many diseases, but there are still challenges in inducing stem cell proliferation and maintaining their stemness. This review discusses the latest research progress in autologous hematopoietic stem cells and induced pluripotent stem cells, and explores the application prospects and existing obstacles.